Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company addressing metabolic dysfunction from excess cortisol. Leveraging underappreciated scientific insights into corticosteroid biology, the company is working to deliver improved outcomes for patients who struggle to control diabetes and related metabolic conditions with current options. Its lead product, clofutriben, is an oral, small molecule designed to target the source of active intracellular cortisol in key tissues. The company was founded in 2013 by David A. Katz and is based in Portland, Oregon, United States.